121 related articles for article (PubMed ID: 17942308)
1. Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies.
Xiang MA; Rybczynski PJ; Patel M; Chen RH; McComsey DF; Zhang HC; Gunnet JW; Look R; Wang Y; Minor LK; Zhong HM; Villani FJ; Demarest KT; Damiano BP; Maryanoff BE
Bioorg Med Chem Lett; 2007 Dec; 17(23):6623-8. PubMed ID: 17942308
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.
Gunnet JW; Wines P; Xiang M; Rybczynski P; Andrade-Gordon P; de Garavilla L; Parry TJ; Cheung WM; Minor L; Demarest KT; Maryanoff BE; Damiano BP
Eur J Pharmacol; 2008 Aug; 590(1-3):333-42. PubMed ID: 18599033
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and evaluation of spirobenzazepines as potent vasopressin receptor antagonists.
Xiang MA; Chen RH; Demarest KT; Gunnet J; Look R; Hageman W; Murray WV; Combs DW; Patel M
Bioorg Med Chem Lett; 2004 Jun; 14(11):2987-9. PubMed ID: 15125974
[TBL] [Abstract][Full Text] [Related]
4. Vascular effects of RWJ-676070, a selective combined V1a/V2 vasopressin receptor antagonist.
Coltamai L; Bucher M; Maillard MP; Shukla U; Bohidar N; Haskell L; Bertelsen K; Fedgchin M; Vogt B; Burnier M
Clin Pharmacol Ther; 2009 Feb; 85(2):145-8. PubMed ID: 18987622
[No Abstract] [Full Text] [Related]
5. Synthesis and evaluation of nonpeptide substituted spirobenzazepines as potent vasopressin antagonists.
Xiang MA; Chen RH; Demarest KT; Gunnet J; Look R; Hageman W; Murray WV; Combs DW; Rybczynski PJ; Patel M
Bioorg Med Chem Lett; 2004 Jun; 14(12):3143-6. PubMed ID: 15149662
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological activity of novel 4,4-difluorobenzazepine derivatives as non-peptide antagonists of the arginine vasopressin V1A receptor.
Shimada Y; Taniguchi N; Matsuhisa A; Akane H; Kawano N; Suzuki T; Tobe T; Kakefuda A; Yatsu T; Tahara A; Tomura Y; Kusayama T; Wada K; Tsukada J; Orita M; Tsunoda T; Tanaka A
Bioorg Med Chem; 2006 Mar; 14(6):1827-37. PubMed ID: 16290163
[TBL] [Abstract][Full Text] [Related]
7. Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist.
Gunnet JW; Matthews JM; Maryanoff BE; de Garavilla L; Andrade-Gordon P; Damiano B; Hageman W; Look R; Stahle P; Streeter AJ; Wines PG; Demarest KT
Clin Exp Pharmacol Physiol; 2006 Apr; 33(4):320-6. PubMed ID: 16620295
[TBL] [Abstract][Full Text] [Related]
8. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
[TBL] [Abstract][Full Text] [Related]
9. Identification and synthesis of major metabolites of Vasopressin V2-receptor agonist WAY-151932, and antagonist, Lixivaptan.
Molinari AJ; Trybulski EJ; Bagli J; Croce S; Considine J; Qi J; Ali K; Demaio W; Lihotz L; Cochran D
Bioorg Med Chem Lett; 2007 Nov; 17(21):5796-800. PubMed ID: 17855087
[TBL] [Abstract][Full Text] [Related]
10. Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.
Ogawa H; Yamashita H; Kondo K; Yamamura Y; Miyamoto H; Kan K; Kitano K; Tanaka M; Nakaya K; Nakamura S; Mori T; Tominaga M; Yabuuchi Y
J Med Chem; 1996 Aug; 39(18):3547-55. PubMed ID: 8784453
[TBL] [Abstract][Full Text] [Related]
11. Conivaptan Yamanouchi.
Doggrell SA
Curr Opin Investig Drugs; 2005 Mar; 6(3):317-26. PubMed ID: 15816509
[TBL] [Abstract][Full Text] [Related]
12. SR-121463. Sanofi-Synthélabo.
Martinez-Castelao A
Curr Opin Investig Drugs; 2001 Oct; 2(10):1423-7. PubMed ID: 11890358
[TBL] [Abstract][Full Text] [Related]
13. The effect of vasopressin and related compounds at V1a and V2 receptors in animal models relevant to human disease.
Petersen MB
Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):96-103. PubMed ID: 16918709
[TBL] [Abstract][Full Text] [Related]
14. Conivaptan: a selective vasopressin antagonist for the treatment of heart failure.
Schwarz ER; Sanghi P
Expert Rev Cardiovasc Ther; 2006 Jan; 4(1):17-23. PubMed ID: 16375624
[TBL] [Abstract][Full Text] [Related]
15. Conivaptan: a dual vasopressin receptor v1a/v2 antagonist [corrected].
Ali F; Raufi MA; Washington B; Ghali JK
Cardiovasc Drug Rev; 2007; 25(3):261-79. PubMed ID: 17919259
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic properties of YM218, a novel, potent, nonpeptide vasopressin V1A receptor-selective antagonist.
Tsukada J; Tahara A; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
Vascul Pharmacol; 2005 Jan; 42(2):47-55. PubMed ID: 15722249
[TBL] [Abstract][Full Text] [Related]
17. Effects of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on vasopressin-induced growth responses in human mesangial cells.
Tahara A; Tsukada J; Tomura Y; Momose K; Suzuki T; Yatsu T; Shibasaki M
Eur J Pharmacol; 2006 May; 538(1-3):32-8. PubMed ID: 16678155
[TBL] [Abstract][Full Text] [Related]
18. Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats.
Takeuchi M; Lee JD; Shimizu H; Ueda T
Int J Cardiol; 2006 Apr; 108(2):231-6. PubMed ID: 16002161
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.
Tsukamoto I; Koshio H; Kuramochi T; Saitoh C; Yanai-Inamura H; Kitada-Nozawa C; Yamamoto E; Yatsu T; Shimada Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2009 Apr; 17(8):3130-41. PubMed ID: 19321349
[TBL] [Abstract][Full Text] [Related]
20. Role of vasopressin antagonists.
Torres VE
Clin J Am Soc Nephrol; 2008 Jul; 3(4):1212-8. PubMed ID: 18434616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
